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Background: Mucoepidermoid carcinoma (MEC) of the lung is a rare subtype of non-small cell
lung cancer. There is no consensus regarding optimal management for this disease.
Case report: We  present a case of MEC of the lung in a 75 year-old female with a history of
superﬁcial urothelial carcinoma of the bladder. The patient was found to have an asymp-
tomatic lung mass. Initial biopsy suggested metastatic recurrence of urothelial carcinoma
and therefore, cisplatin and gemcitabine chemotherapy was administered prior to surgical
resection. Pathological analysis of the resected specimen conﬁrmed a diagnosis of stage IIIA
MEC with focal high-grade features including transitional cell-like areas. Adjuvant radiothe-
rapy was administered due to a positive microscopic resection margin. No chemotherapy
was given due to lack of supporting data. The patient developed widespread metastatic
disease 3 months following completion of radiotherapy and died 1 month later.Conclusion: This case demonstrates the possibility of dual pathology in cases where
metastatic disease is suspected. The use of small tissue samples may complicate diagnosis
due  to the heterogeneity of malignant tumours.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
history underwent a radical cystectomy for a urinary bladder
tumour causing bilateral hydronephrosis. No distant disease
was identiﬁed on CT imaging. Pathology revealed a grade
II, 10 cm superﬁcial urothelial carcinoma without muscle1.  Introduction
Mucoepidermoid carcinoma (MEC) of the lung is a rare tumour
subtype comprising approximately 0.1% of lung cancers.1
There is no consensus for its management. We  present a case
of asymptomatic MEC  of lung identiﬁed on follow-up imaging
for another malignancy.∗ Corresponding author at: Department of Medical Oncology, Mercy Univ
fax:  +353 21 2305041.
E-mail address: drdonnagraham@gmail.com (D.M. Graham).
1507-1367/$ – see front matter © 2013 Greater Poland Cancer Centre. Publish
http://dx.doi.org/10.1016/j.rpor.2013.07.004rights reserved.
2.  Case
A 75 year-old, Caucasian female with a 50 pack-year smokingersity Hospital, Grenville Place, Cork, Ireland. Tel.: +353 86 2361330;
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Fig. 1 – Biopsy sample (high power 20×)  demonstrated
ﬁbrotic tissue incorporating islands of monomorphic cells
with plentiful eosinophilic cytoplasm. An occasional
mitotic and apoptotic ﬁgure was identiﬁed.
Immunohistochemical staining was positive for CK7, CK20
and AE1/3 and negative for TTF-1, suggesting urothelial
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marcinoma.
nvasion (Ta N0 M0).2 No adjuvant therapy was given. Three
ears later, routine chest X-ray demonstrated a lesion in the
eft upper lobe. Computed tomography (CT) conﬁrmed an
solated lesion in the lingula measuring 5.2 cm in the max-
mal diameter. Pathological analysis of a core needle biopsy
f the lesion, when compared with the previously resected
ladder tumour, suggested the possibility of metastasis from
he prior bladder tumour (Fig. 1). Cystoscopic examination of
he bladder did not demonstrate any evidence of local recur-
ence. Multidisciplinary team discussion was focused on the
arly stage of the prior bladder tumour and the low probabil-
ty of development of metastatic disease. Despite this, there
as a distinct similarity between the core needle biopsy of
he current lesion and the prior bladder sample on patho-
ogical review. Therefore, a trial of systemic chemotherapy
as recommended, followed by consideration of surgery or
adiation therapy. Platinum and gemcitabine chemotherapy
as administered over a 2-month period and treatment was
ig. 2 – Resection specimen. H&E staining of tumour showing (a)
brous stroma, (b) PAS-D stain highlights cellular mucin in the g
ucoepidermoid carcinoma and (c) transitional cell-like areas siiotherapy 1 9 ( 2 0 1 4 ) 62–64 63
stopped early secondary to persistent myelosuppression. Posi-
ton Emission Tomography (PET) scan conﬁrmed no further
metastatic disease but low to moderate FDG uptake was
noted within normal sized right sided hilar nodes (maximum
SUV 3.5) and a modiﬁed lingular resection of the lung was
performed. Pathology revealed a non-small cell lung carci-
noma (NSCLC)/MEC with focal high-grade features including
transitional cell-like areas (pT2b, pN2), stage IIIA2 (Fig. 2).
Immunohistochemical staining highlighted diffuse positivity
for AE1/AE3, p63 and CK7. There was focal CK20, MOC31,
BerEp4 and CK5/6 positivity. TTF-1 and Napsin A were nega-
tive within the lesional cells. Epidermal growth factor receptor
(EGFR) analysis demonstrated the absence of classical activat-
ing mutations in exon 19 and 21. In view of positive resection
margins and positive lymph nodes, adjuvant radiotherapy was
delivered. The target volume was the left hilum and ipsilateral
mediastinal lymph nodes including the subcarinal area. 60 Gy
in 30 fractions was delivered using a 3D-conformal technique.
Following multidisciplinary discussion, adjuvant chemother-
apy was not given due to the paucity of supporting data, and
lack of response to initial platinum-based therapy.
The patient subsequently presented with increasing
shortness of breath and back pain 3 months following radio-
therapy. CT and magnetic resonance (MR) imaging conﬁrmed
widespread metastatic disease involving both lungs, multiple
nodal sites, bony pelvis and multiple vertebrae. ECOG perfor-
mance status was 3.3 Radiotherapy was administered to the
lumbar spine and left hip for pain control. Systemic therapy
was not administered. The patient was referred to palliative
care and passed away 3 weeks later.
3.  Discussion
MEC  originates from minor salivary gland tissue of the tra-
cheobronchial tree and is the most common primary salivary
gland carcinoma.4 It can also occur as a rare subtype of NSCLC
and usually occurs in the central bronchial region.1 Patholog-glands and can be divided into low-grade or high-grade vari-
ants. Low-grade tumours tend to contain a higher portion of
mucous cells and high-grade tumours are distinguished by
 areas of clear cells and glandular areas embedded within
landular spaces and in lesional cells consistent with
milar to the initial biopsy.
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poorly-differentiated cells, mitoses and necrosis.5 EGFR muta-
tions have been reported in all grades of these tumours.6,7
It has also been noted that bronchopulmonary MEC  have
chromosomal abnormalities in common with MEC of the sali-
vary glands. The major chromosomal abnormality in MEC  of
salivary glands is the translocation t(11;19)(q21;p13) resulting
in the fusion of mucoepidermoid carcinoma translocated 1-
mammalian mastermind-like 2 genes. This has been detected
in MEC  of the lung but is not found in other subtypes of
NSCLC.8
In localised bronchopulmonary MEC, surgical resection is
the treatment of choice with re-excision in the case of posi-
tive margins.9 However, adjuvant radiotherapy may be used in
the case of positive margins where re-excision is not possible.
There are little data on adjuvant chemotherapy after surgical
resection. In the metastatic setting, the most common sites of
disease are lymph nodes, lung and bone (as in our case), brain
and adrenal glands. However, metastases have been noted,
in rare cases, to the kidney, pleura, pericardium, muscle,
skin and gastrointestinal tract.10–14 High-grade tumours are
thought to be relatively chemotherapy insensitive. Although
a varied selection of chemotherapeutic agents and EGFR-
targeted tyrosine kinase inhibitors have been administered
to small numbers of patients in this setting with contrasting
responses,7,9,15–17 the evidence-base for systemic therapy
remains poor.
4.  Conclusion
Urothelial carcinoma may be confused with other histologies
and MECs are composed of varying proportions of squa-
mous, mucous and intermediate cell types.5 In our case,
the presence of a transitional cell-like area within MEC
led to a histological diagnosis on limited biopsy material
suggesting urothelial carcinoma. This resulted in preoper-
ative chemotherapy being delivered, which may not have
been ideal management. This case demonstrates the impor-
tance of the possibility of dual pathology in situations
where metastatic disease is suspected radiologically. The
inherent heterogeneity of malignant tumours18 may lead to
diagnostic confusion. Therefore, adequate tissue is essen-
tial in order to accurately diagnose and optimally treat
malignancy.
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